J. B. Chemicals & Pharmaceuticals Limited

BSE:506943 Stock Report

Market Cap: ₹260.8b

J. B. Chemicals & Pharmaceuticals Valuation

Is 506943 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 506943 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 506943 (₹1679.15) is trading above our estimate of fair value (₹560.77)

Significantly Below Fair Value: 506943 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 506943?

Key metric: As 506943 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 506943. This is calculated by dividing 506943's market cap by their current earnings.
What is 506943's PE Ratio?
PE Ratio42.7x
Earnings₹6.11b
Market Cap₹260.80b

Price to Earnings Ratio vs Peers

How does 506943's PE Ratio compare to its peers?

The above table shows the PE ratio for 506943 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average88.4x
GLAND Gland Pharma
42.2x25.8%₹292.2b
524558 Neuland Laboratories
68.9x33.9%₹192.8b
LAURUSLABS Laurus Labs
198.9x55.6%₹260.8b
EMCURE Emcure Pharmaceuticals
43.5x25.3%₹246.8b
506943 J. B. Chemicals & Pharmaceuticals
42.7x19.4%₹260.8b

Price-To-Earnings vs Peers: 506943 is good value based on its Price-To-Earnings Ratio (42.7x) compared to the peer average (88.4x).

Price to Earnings Ratio vs Industry

How does 506943's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.79m
524652 Ind-Swift
2xn/aUS$13.15m
No more companies available in this PE range
506943 42.7xIndustry Avg. 32.4xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 506943 is expensive based on its Price-To-Earnings Ratio (42.7x) compared to the Indian Pharmaceuticals industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is 506943's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

506943 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.7x
Fair PE Ratio41.6x

Price-To-Earnings vs Fair Ratio: 506943 is expensive based on its Price-To-Earnings Ratio (42.7x) compared to the estimated Fair Price-To-Earnings Ratio (41.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 506943 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,679.15
₹2,173.77
+29.5%
8.4%₹2,330.00₹1,686.00n/a13
Nov ’25₹1,961.80
₹2,118.00
+8.0%
8.5%₹2,343.00₹1,651.00n/a13
Oct ’25₹1,835.40
₹2,105.69
+14.7%
8.1%₹2,255.00₹1,651.00n/a13
Sep ’25₹1,949.80
₹2,086.17
+7.0%
8.1%₹2,230.00₹1,651.00n/a12
Aug ’25₹1,913.45
₹1,975.42
+3.2%
7.3%₹2,200.00₹1,631.00n/a12
Jul ’25₹1,791.30
₹1,975.42
+10.3%
7.3%₹2,200.00₹1,631.00n/a12
Jun ’25₹1,764.25
₹1,929.83
+9.4%
10.1%₹2,200.00₹1,519.00n/a12
May ’25₹1,904.10
₹1,881.73
-1.2%
10.1%₹2,200.00₹1,500.00n/a11
Apr ’25₹1,687.30
₹1,886.70
+11.8%
10.9%₹2,200.00₹1,500.00n/a10
Mar ’25₹1,532.75
₹1,886.70
+23.1%
10.9%₹2,200.00₹1,500.00n/a10
Feb ’25₹1,683.35
₹1,746.80
+3.8%
8.3%₹1,970.00₹1,471.00n/a10
Jan ’25₹1,612.75
₹1,689.80
+4.8%
8.0%₹1,860.00₹1,367.00n/a10
Dec ’24₹1,459.20
₹1,566.32
+7.3%
11.4%₹1,775.00₹1,137.50n/a11
Nov ’24₹1,400.55
₹1,465.27
+4.6%
10.9%₹1,657.00₹1,137.50₹1,961.8011
Oct ’24₹1,483.65
₹1,465.23
-1.2%
10.9%₹1,657.00₹1,137.50₹1,835.4011
Sep ’24₹1,398.28
₹1,422.05
+1.7%
12.3%₹1,657.00₹1,137.50₹1,949.8011
Aug ’24₹1,286.88
₹1,181.75
-8.2%
8.0%₹1,340.00₹951.50₹1,913.4512
Jul ’24₹1,183.15
₹1,179.25
-0.3%
7.9%₹1,340.00₹951.50₹1,791.3012
Jun ’24₹1,056.68
₹1,164.64
+10.2%
7.2%₹1,268.00₹951.50₹1,764.2511
May ’24₹1,065.45
₹1,138.40
+6.8%
6.0%₹1,237.50₹1,040.00₹1,904.1010
Apr ’24₹985.45
₹1,137.40
+15.4%
6.1%₹1,237.50₹1,030.00₹1,687.3010
Mar ’24₹996.43
₹1,137.40
+14.1%
6.1%₹1,237.50₹1,030.00₹1,532.7510
Feb ’24₹1,011.60
₹1,140.55
+12.7%
4.8%₹1,230.00₹1,050.00₹1,683.3510
Jan ’24₹971.68
₹1,140.55
+17.4%
4.8%₹1,230.00₹1,050.00₹1,612.7510
Dec ’23₹1,009.48
₹1,146.19
+13.5%
4.7%₹1,230.00₹1,050.00₹1,459.208
Nov ’23₹999.33
₹1,064.19
+6.5%
7.6%₹1,194.50₹965.00₹1,400.558

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

IOL Chemicals and Pharmaceuticals

₹20.5b

Manufactures and sells pharmaceutical and chemical products in India and internationally.

IOLCP

₹348.90

7D

-11.3%

1Y

-16.9%

Solara Active Pharma Sciences

₹35.8b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

SOLARAPP

₹458.00

7D

-3.8%

1Y

n/a

Caplin Point Laboratories

₹150.9b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,988.75

7D

-1.2%

1Y

56.6%